The European Organization for research and Treatment of Cancer Melanoma Group Trial Experience with more than 2000 Patients, evaluating adjuvant therapy treatment with low or intermediate doses of Interferon Alpha-2b

Lex Eggermont; UR Kleeberg; DJ Ruiter; S Suciu

The European Organization for research and Treatment of Cancer Melanoma Group Trial Experience with more than 2000 Patients, evaluating adjuvant therapy treatment with low or intermediate doses of Interferon Alpha-2b

Lex Eggermont, UR Kleeberg, DJ Ruiter, S Suciu

Surgery

Research output: Chapter/Conference proceeding › Chapter › Academic

Original language	Undefined/Unknown
Title of host publication	Educational Book 37th Annual Meeting
Editors	M.C. Perry
Place of Publication	Alexandria USA
Publisher	American Society of Clinical Oncology
Pages	88-93
Number of pages	6
ISBN (Print)	0966449541
Publication status	Published - 2001

Research programs

EMC MM-03-47-11

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Eggermont, L., Kleeberg, UR., Ruiter, DJ., & Suciu, S. (2001). The European Organization for research and Treatment of Cancer Melanoma Group Trial Experience with more than 2000 Patients, evaluating adjuvant therapy treatment with low or intermediate doses of Interferon Alpha-2b. In M. C. Perry (Ed.), Educational Book 37th Annual Meeting (pp. 88-93). American Society of Clinical Oncology.

Eggermont, Lex ; Kleeberg, UR ; Ruiter, DJ et al. / The European Organization for research and Treatment of Cancer Melanoma Group Trial Experience with more than 2000 Patients, evaluating adjuvant therapy treatment with low or intermediate doses of Interferon Alpha-2b. Educational Book 37th Annual Meeting. editor / M.C. Perry. Alexandria USA : American Society of Clinical Oncology, 2001. pp. 88-93

@inbook{2613d50dbb7547318aaccdb8b2920af2,

title = "The European Organization for research and Treatment of Cancer Melanoma Group Trial Experience with more than 2000 Patients, evaluating adjuvant therapy treatment with low or intermediate doses of Interferon Alpha-2b",

author = "Lex Eggermont and UR Kleeberg and DJ Ruiter and S Suciu",

year = "2001",

language = "Undefined/Unknown",

isbn = "0966449541",

pages = "88--93",

editor = "M.C. Perry",

booktitle = "Educational Book 37th Annual Meeting",

publisher = "American Society of Clinical Oncology",

address = "United States",

}

Eggermont, L, Kleeberg, UR, Ruiter, DJ & Suciu, S 2001, The European Organization for research and Treatment of Cancer Melanoma Group Trial Experience with more than 2000 Patients, evaluating adjuvant therapy treatment with low or intermediate doses of Interferon Alpha-2b. in MC Perry (ed.), Educational Book 37th Annual Meeting. American Society of Clinical Oncology, Alexandria USA, pp. 88-93.

The European Organization for research and Treatment of Cancer Melanoma Group Trial Experience with more than 2000 Patients, evaluating adjuvant therapy treatment with low or intermediate doses of Interferon Alpha-2b. / Eggermont, Lex; Kleeberg, UR; Ruiter, DJ et al.
Educational Book 37th Annual Meeting. ed. / M.C. Perry. Alexandria USA: American Society of Clinical Oncology, 2001. p. 88-93.

Research output: Chapter/Conference proceeding › Chapter › Academic

TY - CHAP

T1 - The European Organization for research and Treatment of Cancer Melanoma Group Trial Experience with more than 2000 Patients, evaluating adjuvant therapy treatment with low or intermediate doses of Interferon Alpha-2b

AU - Eggermont, Lex

AU - Kleeberg, UR

AU - Ruiter, DJ

AU - Suciu, S

PY - 2001

Y1 - 2001

M3 - Chapter

SN - 0966449541

SP - 88

EP - 93

BT - Educational Book 37th Annual Meeting

A2 - Perry, M.C.

PB - American Society of Clinical Oncology

CY - Alexandria USA

ER -

Eggermont L, Kleeberg UR, Ruiter DJ, Suciu S. The European Organization for research and Treatment of Cancer Melanoma Group Trial Experience with more than 2000 Patients, evaluating adjuvant therapy treatment with low or intermediate doses of Interferon Alpha-2b. In Perry MC, editor, Educational Book 37th Annual Meeting. Alexandria USA: American Society of Clinical Oncology. 2001. p. 88-93